<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p40" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_40{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_40{left:341px;bottom:30px;}
#t3_40{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_40{left:377px;bottom:30px;}
#t5_40{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_40{left:540px;bottom:30px;}
#t7_40{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_40{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_40{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_40{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_40{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_40{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_40{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_40{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_40{left:1105px;bottom:47px;letter-spacing:0.34px;}
#tg_40{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_40{left:360px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.23px;}
#ti_40{left:545px;bottom:760px;letter-spacing:0.45px;}
#tj_40{left:36px;bottom:742px;letter-spacing:0.08px;}
#tk_40{left:53px;bottom:736px;letter-spacing:0.1px;word-spacing:0.02px;}
#tl_40{left:45px;bottom:719px;letter-spacing:0.12px;}
#tm_40{left:36px;bottom:708px;letter-spacing:0.08px;}
#tn_40{left:53px;bottom:702px;letter-spacing:0.11px;}
#to_40{left:53px;bottom:685px;letter-spacing:0.13px;}
#tp_40{left:36px;bottom:675px;letter-spacing:0.08px;}
#tq_40{left:53px;bottom:669px;letter-spacing:0.12px;word-spacing:-0.04px;}
#tr_40{left:53px;bottom:652px;letter-spacing:0.12px;word-spacing:0.01px;}
#ts_40{left:36px;bottom:641px;letter-spacing:0.08px;}
#tt_40{left:53px;bottom:635px;letter-spacing:0.11px;word-spacing:0.01px;}
#tu_40{left:45px;bottom:618px;letter-spacing:0.12px;word-spacing:0.01px;}
#tv_40{left:36px;bottom:607px;letter-spacing:0.08px;}
#tw_40{left:53px;bottom:601px;letter-spacing:0.11px;word-spacing:-0.02px;}
#tx_40{left:53px;bottom:585px;letter-spacing:0.13px;}
#ty_40{left:36px;bottom:574px;letter-spacing:0.08px;}
#tz_40{left:53px;bottom:568px;letter-spacing:0.12px;word-spacing:0.01px;}
#t10_40{left:53px;bottom:551px;letter-spacing:0.12px;word-spacing:0.01px;}
#t11_40{left:36px;bottom:540px;letter-spacing:0.08px;}
#t12_40{left:53px;bottom:534px;letter-spacing:0.11px;word-spacing:-0.02px;}
#t13_40{left:53px;bottom:517px;letter-spacing:0.13px;}
#t14_40{left:36px;bottom:506px;letter-spacing:0.08px;}
#t15_40{left:53px;bottom:501px;letter-spacing:0.12px;}
#t16_40{left:53px;bottom:484px;letter-spacing:0.08px;word-spacing:-0.02px;}
#t17_40{left:36px;bottom:473px;letter-spacing:0.08px;}
#t18_40{left:53px;bottom:467px;letter-spacing:0.11px;word-spacing:-0.03px;}
#t19_40{left:36px;bottom:456px;letter-spacing:0.08px;}
#t1a_40{left:53px;bottom:450px;letter-spacing:0.09px;word-spacing:0.03px;}
#t1b_40{left:53px;bottom:433px;letter-spacing:0.11px;word-spacing:-0.12px;}
#t1c_40{left:36px;bottom:422px;letter-spacing:0.08px;}
#t1d_40{left:53px;bottom:417px;letter-spacing:0.11px;word-spacing:0.01px;}
#t1e_40{left:53px;bottom:400px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1f_40{left:36px;bottom:389px;letter-spacing:0.08px;}
#t1g_40{left:53px;bottom:383px;letter-spacing:0.12px;}
#t1h_40{left:53px;bottom:366px;letter-spacing:0.13px;}
#t1i_40{left:36px;bottom:355px;letter-spacing:0.08px;}
#t1j_40{left:53px;bottom:349px;letter-spacing:0.09px;word-spacing:0.02px;}
#t1k_40{left:53px;bottom:332px;letter-spacing:0.12px;word-spacing:0.02px;}
#t1l_40{left:36px;bottom:322px;letter-spacing:0.08px;}
#t1m_40{left:53px;bottom:316px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t1n_40{left:53px;bottom:299px;letter-spacing:0.13px;}
#t1o_40{left:36px;bottom:288px;letter-spacing:0.08px;}
#t1p_40{left:53px;bottom:282px;letter-spacing:0.09px;word-spacing:-0.04px;}
#t1q_40{left:53px;bottom:265px;letter-spacing:0.12px;word-spacing:-0.04px;}
#t1r_40{left:36px;bottom:254px;letter-spacing:0.08px;}
#t1s_40{left:53px;bottom:248px;letter-spacing:0.1px;word-spacing:-0.01px;}
#t1t_40{left:53px;bottom:232px;letter-spacing:0.13px;}
#t1u_40{left:36px;bottom:221px;letter-spacing:0.08px;}
#t1v_40{left:53px;bottom:215px;letter-spacing:0.12px;}
#t1w_40{left:53px;bottom:198px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1x_40{left:36px;bottom:187px;letter-spacing:0.08px;}
#t1y_40{left:53px;bottom:181px;letter-spacing:0.12px;word-spacing:-0.07px;}
#t1z_40{left:53px;bottom:164px;letter-spacing:0.12px;word-spacing:0.01px;}
#t20_40{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_40{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_40{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_40{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_40{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_40{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_40{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_40{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_40{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_40{font-size:15px;font-family:ArialMT_k0;color:#000;}
.s9_40{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts40" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg40Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg40" style="-webkit-user-select: none;"><object width="1210" height="935" data="40/40.svg" type="image/svg+xml" id="pdf40" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_40" class="t s0_40">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_40" class="t s1_40">® </span>
<span id="t3_40" class="t s0_40">(NCCN </span>
<span id="t4_40" class="t s1_40">® </span>
<span id="t5_40" class="t s0_40">), All rights reserved. NCCN Guidelines </span>
<span id="t6_40" class="t s1_40">® </span>
<span id="t7_40" class="t s0_40">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_40" class="t s2_40">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_40" class="t s2_40">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_40" class="t s3_40">NCCN Guidelines Version 4.2024 </span>
<span id="tb_40" class="t s3_40">Cancer of the Nasopharynx </span>
<span id="tc_40" class="t s4_40">NCCN Guidelines Index </span>
<span id="td_40" class="t s4_40">Table of Contents </span>
<span id="te_40" class="t s4_40">Discussion </span>
<span id="tf_40" class="t s5_40">NASO-B </span>
<span id="tg_40" class="t s5_40">3 OF 3 </span>
<span id="th_40" class="t s5_40">SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS </span>
<span id="ti_40" class="t s5_40">REFERENCES </span>
<span id="tj_40" class="t s6_40">21 </span>
<span id="tk_40" class="t s7_40">Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a </span>
<span id="tl_40" class="t s7_40">phase II clinical trial (POLARIS-02). J Clin Oncol 2021;39:704-712. </span>
<span id="tm_40" class="t s6_40">22 </span>
<span id="tn_40" class="t s8_40">Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer </span>
<span id="to_40" class="t s7_40">(E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567. </span>
<span id="tp_40" class="t s6_40">23 </span>
<span id="tq_40" class="t s8_40">Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced </span>
<span id="tr_40" class="t s7_40">squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251. </span>
<span id="ts_40" class="t s6_40">24 </span>
<span id="tt_40" class="t s7_40">Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of </span>
<span id="tu_40" class="t s7_40">the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188. </span>
<span id="tv_40" class="t s6_40">25 </span>
<span id="tw_40" class="t s7_40">Chan ATC, Hsu M-M, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal </span>
<span id="tx_40" class="t s7_40">carcinoma. J Clin Oncol 2005;23:3568-3576. </span>
<span id="ty_40" class="t s6_40">26 </span>
<span id="tz_40" class="t s8_40">Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head </span>
<span id="t10_40" class="t s7_40">and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654. </span>
<span id="t11_40" class="t s6_40">27 </span>
<span id="t12_40" class="t s8_40">Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced </span>
<span id="t13_40" class="t s7_40">squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263. </span>
<span id="t14_40" class="t s6_40">28 </span>
<span id="t15_40" class="t s7_40">Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University </span>
<span id="t16_40" class="t s7_40">Study. Cancer Treat Rep 1987;71:723-726. </span>
<span id="t17_40" class="t s6_40">29 </span>
<span id="t18_40" class="t s7_40">Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129:1294-1299. </span>
<span id="t19_40" class="t s6_40">30 </span>
<span id="t1a_40" class="t s7_40">Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and </span>
<span id="t1b_40" class="t s7_40">neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-537. </span>
<span id="t1c_40" class="t s6_40">31 </span>
<span id="t1d_40" class="t s7_40">Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck </span>
<span id="t1e_40" class="t s7_40">cancer. Eur J Cancer 2004;40:2071-2076. </span>
<span id="t1f_40" class="t s6_40">32 </span>
<span id="t1g_40" class="t s7_40">Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and </span>
<span id="t1h_40" class="t s7_40">neck [corrected]. J Clin Oncol 2009;27:1864-1871. </span>
<span id="t1i_40" class="t s6_40">33 </span>
<span id="t1j_40" class="t s7_40">Zhang L, Zhang Y, Huang P-Y, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of </span>
<span id="t1k_40" class="t s7_40">platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:33-38. </span>
<span id="t1l_40" class="t s6_40">34 </span>
<span id="t1m_40" class="t s8_40">Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck </span>
<span id="t1n_40" class="t s7_40">cancer after previous platinum-based treatment. Br J Cancer 2010;102:1687-1691. </span>
<span id="t1o_40" class="t s6_40">35 </span>
<span id="t1p_40" class="t s7_40">Delord JP, Hollebecque A, de Boer JP, et al. An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate </span>
<span id="t1q_40" class="t s7_40">358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) [abstract]. J Clin Oncol 2017;35(suppl 15): Abstract 6025. </span>
<span id="t1r_40" class="t s6_40">36 </span>
<span id="t1s_40" class="t s7_40">Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the </span>
<span id="t1t_40" class="t s7_40">Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol 2018;36:1412-1418. </span>
<span id="t1u_40" class="t s6_40">37 </span>
<span id="t1v_40" class="t s8_40">Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results </span>
<span id="t1w_40" class="t s7_40">of the KEYNOTE-028 study. J Clin Oncol 2017;35:4050-4056. </span>
<span id="t1x_40" class="t s6_40">36 </span>
<span id="t1y_40" class="t s8_40">Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: </span>
<span id="t1z_40" class="t s7_40">prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353-1365. </span>
<span id="t20_40" class="t s9_40">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
